Lactobacillus gasseri (probiotic): benefits, dosage, contraindications
Family or group:
Probiotics
Indications
Rating methodology
EFSA approval.
Weight control ✪✪✪✪✪
Consumption of Lactobacillus gasseri allows a reduction of abdominal adiposity. A randomized, double-blind, placebo-controlled trial from a 2010 Japanese scientific study conducted on 87 healthy adults but with high abdominal adiposity (overweight) was conducted to evaluate the effects of the L. gasseri SBT2055 strain on abdominal adiposity and weight. The results show that the group treated with an intake of L. gasseri SBT2055 for 12 weeks lost 4.6% of abdominal fat and 3.3% of subcutaneous fat compared to the control group. Similarly, their body weight, waist circumference, and BMI decreased by 1.4% (1.1 kg), 1.8% (1.7 cm), and 1.5% (0.4 kg/m2), respectively. Another randomized, double-blind, placebo-controlled trial conducted on 90 volunteers aged 20 to 75 observed a significant reduction in visceral adiposity in obese adults. These studies have shown the beneficial effect of supplementation with L. gasseri to significantly reduce abdominal and visceral adiposity in overweight or obese humans. In a 2015 clinical study, published in the journal Lipids Health Disease, more was learned about the mechanism of this bacterial strain. In this study, Japanese researchers demonstrated that the L. gasseri SBT2055 strain suppresses fatty acid release by increasing the size of micelle particles, thus worsening the action of the enzyme involved in the absorption of dietary lipids, the pancreatic lipase. Moreover, the same research team found in humans that consuming fermented milk with L. gasseri SBT2055 led to an increase in fecal fat excretion. This effect could be associated with the inhibition of fat degradation observed in vitro. According to this study, L. gasseri clearly limits fat absorption at the intestinal level.
Posologie
Oral route
Lactobacillus gasseri SBT2055 suppresses fatty acid release through enlargement of fat emulsion size in vitro and promotes fecal fat excretion in healthy Japanese subjects
Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial
Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial
Helicobacter pylori infection ✪✪✪✪✪
Meta-analyses of clinical research show that taking lactobacillus can improve H. pylori eradication rates by 1.14 to 1.24 times when combined with a triple therapy regimen consisting of a proton pump inhibitor (PPI), clarithromycin, and amoxicillin. Specific lactobacillus species that have shown benefits in treating H. pylori infections include L. gasseri one billion colony-forming units (CFUs) twice daily for 4 to 8 weeks, starting 3 weeks before the triple therapy, a lyophilized and inactivated culture of L. acidophilus containing L. acidophilus L.B 5 billion. acidophilus L.B 5 billion heat-killed cells three times daily for 10 days, and a blend of two strains of L. reuteri (DSM 17938 and ATCC PTA 6475; e.g., Gastrus, BioGaia AB) 100 million CFUs of each strain once daily for about 14 weeks, before and after the triple therapy.
Posologie
Oral route
2 UI
Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection
Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy
The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis
Endometriosis ✪✪✪✪✪
According to a 2011 Cytotechnology publication, oral intake of L. gasseri OLL2809 effectively reduces menstrual pain and dysmenorrhea associated with endometriosis compared to a placebo, suggesting that L. gasseri OLL2809 is beneficial for improving the quality of life in patients with endometriosis. L. gasseri OLL2809 might contribute to pain relief by increased generation of IL-12, known to induce proliferation and cytotoxicity of NK cells. Previous research has suggested that endometriotic cells are natural target cells for NK cells, and impaired clearance of ectopic endometrium by NK cells in the peritoneal cavity contributes to the development of the disease.
Posologie
Oral route
Properties
Antibacterial
Some research suggests that lactobacilli are capable of reducing the adherence of pathogenic bacteria to the colonic mucosa and reducing bacterial translocation, which could make them useful in preventing infections and treating diseases such as Crohn's disease. The antimicrobial activity, in vitro, of L. gasseri LA39 has been established against different pathogens: Listeria monocytogenes, Bacillus cereus, and Staphylococcus aureus. Like all lactic bacteria, L. gasseri also produces organic acids. Moreover, it metabolizes glucose into lactic acid. This lactic acid secretion induces acidification capable of inhibiting pathogenic bacteria. Furthermore, it has been observed in vitro, the strain Lactobacillus gasseri, inhibited the adhesion and colonization of Escherichia coli bacteria at the intestinal mucosa.
Usages associés
Anti-inflammatory
Lactobacillus gasseri helps combat inflammation. More specifically, data suggest that Lactobacillus gasseri, both in vitro and in vivo, can significantly decrease the plasma release of inflammation mediators such as pro-inflammatory cytokines. At the same time, this probiotic induces an increase in regulatory cytokines of inflammation. Besides, a randomized double-blind placebo-controlled study was conducted on 32 healthy elderly subjects over three weeks, taking twice daily a probiotic mixture (Lactobacillus. gasseri KS-13, Bifidobacterium longum MM2, B. bifidum G9-1). Researchers evaluated the interest of this supplementation on various parameters: the circulatory CD4+ lymphocyte count, cytokine production, and the microbiota shift towards a healthy bacterial population. The intake of this high concentration probiotic formulation maintained CD4+ lymphocytes and decreased the inflammatory cytokine profile. The hypothesis put forward by the researchers is a normalization in microbial communities, more closely resembling those reported in healthier, younger populations. More broadly, numerous studies have clearly established that Lactobacillus gasseri has a natural resistance allowing it to survive the gastric acidity. It would thereby provide better protection against inflammation encountered in cases of gastritis, stomach ulcers, including ulcers associated with a Helicobacter pylori infection, and irritable bowel syndrome.
Usages associés
Immuno-modulator
Some researchers believe that lactobacilli and other probiotics could have immunomodulatory effects. Lactobacilli seem to modulate both non-specific cellular and humoral immunity, probably by stimulating the activity of lymphocytes and macrophages and modulating cytokine production by mononuclear cells. A double-blind placebo-controlled clinical study of two lactobacilli strains, L. gasseri CECT5714 and L. coryniformis CECT5711, was conducted on 50 healthy adults in comparison with traditional yogurt consumption. The results demonstrate that consumption of the two strains, as well as yogurt, produces a significant increase in phagocytic cells (monocytes and neutrophils) after two weeks (and persists at four weeks) with little difference between the two groups. However, a significant difference was observed in the increase of natural killer NK cells favoring the two new strains; the effect being more pronounced at two weeks than four.
Metabolic
L. gasseri has been associated with a tendency towards weight loss in lean animals in three studies and four comparisons involving 48 pigs and rats. In obese animals and humans, three studies and three comparisons involving 87 humans and rats found an anti-obesity effect. This effect was consistent between humans and animals. Two L. gasseri strains (SBT2055 and BNR17) have a significant anti-obesity effect in individual studies.
Usages associés
Safety dosage
Adult: 2 UI
The microorganism content ranges from 2 to 12 billion CFU (Colony-Forming Unit)
